To determine the longitudinal trends in serum levels of four myositis‐associated autoantibodies: anti‐Jo‐1, TIF1‐γ, SRP, and Mi‐2 after B cells deletion treatment, researchers tested these auto‐antibody levels via myositis core‐set measures. The gene discussed is TRIM33; the disease is myositis disease.